A Proof of Concept Study to Investigate the Effect of IPT803 Adjunct Treatment in Patients With Parkinson's Disease
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 26 Nov 2019
Price : $35 *
At a glance
- Drugs IPT-803 (Primary)
- Indications Parkinson's disease
- Focus Proof of concept; Therapeutic Use
- Sponsors Tools4Patient
- 22 Nov 2019 Planned End Date changed from 1 Oct 2019 to 1 Feb 2020.
- 22 Nov 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Dec 2019.
- 22 Nov 2019 Status changed from recruiting to active, no longer recruiting.